awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q31163540-FC85A188-413A-47D3-BE23-D8DA5F47C441
Q31163540-FC85A188-413A-47D3-BE23-D8DA5F47C441
BestRank
Statement
http://www.wikidata.org/entity/statement/Q31163540-FC85A188-413A-47D3-BE23-D8DA5F47C441
Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.
P2860
Q31163540-FC85A188-413A-47D3-BE23-D8DA5F47C441
BestRank
Statement
http://www.wikidata.org/entity/statement/Q31163540-FC85A188-413A-47D3-BE23-D8DA5F47C441
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
293ae9a2b92e6771f0c54efd13c6c3de818f6338
P2860
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.